Eugia Pharma obtains FDA blessing for generic Nolvadex
Breast cancer patients will soon have a new generic treatment.
The Food and Drug Administration has given Aurobindo Pharma’s joint venture, Eugia Pharma the green light for tamoxifen citrate tablets in dosage strengths of 10 mg and 20 mg.
The product is the generic of AstraZeneca’s Nolvadex tablets, 10 mg and 20 mg.
Tamoxifen citrate tablets are indicated for treatment of metastatic breast cancer in women and men; node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation; and reducing the risk of invasive breast cancer.